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Abstract: (1) Background: Prostate cancer (PCa) is characterized by high heterogeneity. The aim of
this study was to investigate molecular alterations underlying PCa development based on proteomics
data. (2) Methods: Liquid chromatography coupled to tandem mass spectrometry was conducted for
22 fresh-frozen tissue specimens from patients with benign prostatic hyperplasia (BPH, n = 5) and
PCa (n = 17). Mann Whitney test was used to define significant differences between the two groups.
Association of protein abundance with PCa progression was evaluated using Spearman correlation,
followed by verification through investigating the Prostate Cancer Transcriptome Atlas. Functional
enrichment and interactome analysis were carried out using Metascape and String. (3) Results:
Proteomics analysis identified 1433 proteins, including 145 proteins as differentially abundant between
patients with PCa and BPH. In silico analysis revealed alterations in several pathways and hallmarks
implicated in metabolism and signalling, represented by 67 proteins. Among the latter, 21 proteins
were correlated with PCa progression at both the protein and mRNA levels. Interactome analysis
of these 21 proteins predicted interactions between Myc proto-oncogene (MYC) targets, protein
processing in the endoplasmic reticulum, and oxidative phosphorylation, with MYC targets having a
central role. (4) Conclusions: Tissue proteomics allowed for characterization of proteins and pathways
consistently affected during PCa development. Further validation of these findings is required.
Keywords: drug target; personalized medicine; prostate cancer; proteomics; tissue
1. Introduction
With more than 1.2 million new cases and almost 360,000 disease-related deaths among men
in 2018, prostate cancer (PCa) has contributed to 13.5% of the diagnosed cancer cases and 6.7% of
cancer-associated deaths in men [1]. The notable difference between incidence and mortality is related to
the fact that significant proportion of prostate tumours are slow-growing, organ-confined tumours that
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are not likely to progress even without treatment [2]. However, some patients experience an aggressive
disease course (life-threatening) that requires immediate therapy [2]. Accurate discrimination between
these two phenotypes is a well-recognized clinical challenge [2]. As a result, both, overtreatment of
patients with low-risk disease and undertreatment of patients experiencing the aggressive disease
are frequently observed [3]. Beyond this aspect, undertreatment also arises from the lack of effective
therapies for advanced disease. Although the 5-year survival is close to 100% for patients with cancer
confined to the prostate, for patients presenting with distant metastasis, the prognosis is poor, with the
5-year survival rate dropping to around 30% [4]. This indicates that PCa-related deaths are the result
of cancer progression and development of metastatic castration-resistant PCa (mCRPC), with a median
survival of 2 to 3 years [5].
Advancements in knowledge on the molecular background of PCa indicated high complexity
and heterogeneity of the disease [6–8]. Even though, over the last decade, new therapies have been
approved in the context of castration-resistant PCa (CRPC) and/or mCRPC [9,10], the low response
rate and the development of resistance as a result of the diverse molecular background of the tumour
stands in the way of improving outcomes. To close this gap, a potential solution may be the global
analysis of tumour samples at the molecular level through advanced –omics approaches to better
understand the mechanisms underlying disease development and to define an array of drug targets and
potential biomarkers to stratify patients for a specific treatment [11]. Among the –omics approaches,
investigation of proteins is expected to provide particularly relevant insights into cancer biology,
as proteins integrate genomic information with environmental impact, regulate all biological functions
and display information on specific disease-altered pathways.
The purpose of this study was to investigate proteomics profiles from malignant and benign
prostate tissue to provide insights into molecular pathophysiology underlying PCa development.
The findings of this proof-of-concept study are expected to build a solid foundation for identification
of drug targets and drug candidates for PCa relying on molecular pathophysiology.
2. Materials and Methods
2.1. Clinical Material
We analysed 22 prostate surgical specimens from patients with clinically and histologically
confirmed PCa and benign prostatic hyperplasia (BPH) obtained from the University Clinic for Urology,
University Clinical Centre “Mother Theresa”, Skopje, Republic of North Macedonia. Informed consent
for the use of these samples for research purposes was obtained from the patients in accordance with
the Declaration of Helsinki. All data were anonymised, and the study was approved by the ethics
committees of the Macedonian Academy of Sciences and Arts (09-1221/1, 10-04-2018) and by the
Hannover Medical School (7975_BO_K_2018, 12-07-2018). The samples used in this study were fresh
surgical tissues from 5 BPH patients obtained by transurethral resection of the prostate gland and
from 17 PCa patients obtained by radical prostatectomy (Table S1). All tissue samples were kept on
ice immediately after surgery to avoid proteolytic degradation and were subsequently snap frozen in
liquid nitrogen within 30 min after surgery. Samples were stored at −80 ◦C. Frozen sections were cut
from the macroscopically visible tumour areas to confirm histologically the presence of cancer. Manual
microdissection was conducted to obtain pathologically characterized materials for our proteomics
approach. All tumour samples contained more than 70% of tumour cells.
2.2. Sample Preparation and Liquid Chromatography Coupled to Tandem Mass Spectrometry
(LC-MS/MS) Analysis
Sample preparation was performed as described in [12–14]. In brief, tissue samples (with net
weight of 10–20 mg) were homogenized with a bullet blender homogenizer (Next Advance, Troy,
NY, US) using stainless steel beads (0.9–2-mm diameter). Homogenization was performed in lysis
buffer comprised of 4% sodium dodecyl sulphate (SDS), 0.1 M dithioerythritol and 0.1 M Tris-HCl
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pH 7.6. Subsequently, the samples were centrifuged at 16,000g for 10 min at room temperature and
the supernatant was kept in clean tubes. Protein concentration was measured with Bradford assay.
Protease inhibitors (Roche, Basel, Switzerland) were added at a final concentration of 3.6% v/v, and the
samples were stored at −80 ◦C until further use. Ten micrograms of each sample were loaded onto
sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE). Protein separation and
tryptic digestion were performed as described in [12–14]. Tryptic digests were dried, resuspended in
mobile phase A buffer (0.1% formic acid, pH 3) and processed with LC-MS/MS analysis, as previously
described [13,14]. Briefly, the peptide mixture was first loaded into a Dionex Ultimate 3000 RSLS nano
flow system (Dionex, Camberly, UK), including an integrated Dionex nano trap column (0.1 × 20 mm,
5 µm, C18). Two percent acetonitrile/0.1% formic acid was applied as a mobile phase, and the flow rate
was set to 5 µL/min. Acclaim PepMap C18 nano column (75 µm × 50 cm, 2 µm 100 Å) was configured
as an analytical column, with a flow rate of 300 nL/min. Peptides were eluted with a gradient of mobile
phase A (0.1% formic acid in water) versus mobile phase B (0.1% formic acid in 80% acetonitrile) as
follows: 1% B for 5 min rising to 5% B at 10 min and then to 25% B at 360 min and 65% B at 480 min.
Electrospray ionisation was applied using a Proxeon nano spray source (positive ion mode) connected
to an Orbitrap LTQ Velos (Thermo Finnigan, Bremen, Germany). The instrument was operated in
MS/MS mode with the scanning range set at 380 to 2000 m/z. An ionization voltage of 2.6 kV and
temperature of the capillary at 275 ◦C were applied, while the resolutions of ions were 60,000 and 7500
in MS1 and MS2 (for higher-energy collisional dissociation, HCD), respectively. The top 20 method
was implemented for selection of the precursor ions from each scan, followed by fragmentation using
HCD at 35% collision energy. Dynamic exclusion was applied with a repeat count of 1 and an exclusion
duration time of 30 s.
2.3. MS Data Processing and Statistical Analysis
RAW mass spectrometry data were processed and analysed as follows [14–16]: Protein
identification was conducted using Proteome Discoverer v1.4 (Thermo Finnigan, San Jose, CA, US)
using the human SwissProt database and the SEQUEST search engine. The FASTA file was downloaded
from the Uniprot database (https://www.uniprot.org/) on 20 June 2019 and included 20,431 reviewed
entries. Only canonical sequences were considered. The following search parameters were applied:
(a) precursor mass tolerance: 10 ppm and fragment mass tolerance: 0.05 Da; (b) full tryptic digestion;
(c) maximum missed cleavage sites: 2; (d) static modifications: carbamidomethylation of cysteine;
and (e) dynamic modifications: oxidation of methionine and proline, deamidation of asparagine and
glutamine, carbamylation of lysine and N-terminal carbamidomethylation. Subsequently, individual
datasets were exported at the peptide level using the following filters: (a) peptide confidence: high,
medium and low; (b) peptide rank up to 5; (c) peptide grouping enabled and protein grouping disabled;
and (d) ∆M ± 5 ppm. Data were further processed using a clustering approach that was described
previously, with some minor modifications [15,16]: peptides from different proteomics analyses were
grouped (“clustered”) based on a predefined mass window of ±5 ppm and retention time of ±5%. To
increase the validity of the reference sequence assignment to the cluster, only sequences that were
determined with high confidence during Proteome Discoverer analysis (false discovery rate, FDR <
1%) were considered. Among them, the sequence with the highest sum of Xcorr across all samples was
accepted as representative for the cluster. This resulted in the generation of the common peptide list
based on all proteomics runs (dataspace) that was subsequently used for protein identification. For
protein identification, when the peptide corresponded to multiple proteins, it was assigned only to one
protein based on Occam’s Razor approach (i.e., protein that was identified with the highest number of
peptides in our dataspace). All identified proteins (independent from the number of peptide–spectrum
matches and assigned peptides) were considered for quantification and normalization. Briefly,
quantification of proteomics data was based on the precursor ion peak area. Abundance for a given
protein was calculated based on the sum of all belonging peptide peak areas [15,16], followed by part
per million (ppm) normalization. Statistical analysis was conducted using Mann Whitney test, and
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differences in protein abundance with p < 0.05 were defined as significant. The Spearman’s rank-order
correlation was employed to identify proteins associated with PCa progression. For the latter, the
protein abundance was correlated with Gleason score (GS) (GS < 7, GS = 7 and GS > 7) from patients
with PCa.
2.4. Bioinformatics Analysis
Functional enrichment analysis for Molecular Signatures Database (MSigDB) hallmark gene
set collection associations was performed using Metascape (https://metascape.org/ [17]). Default
settings were applied (hypergeometric p < 0.01, ≥3 molecules assigned and an enrichment factor >1.5).
Enrichment in the Kyoto encyclopedia of genes and genomes (Kegg) pathways [18] was performed
using String v11.0 (https://string-db.org/) [19]. The latter tool was also used to create protein–protein
interaction networks. In both cases, default settings were applied [19]. Protein class was assigned
based on the Panther Classification System (http://www.pantherdb.org/ [20]).
2.5. Transcriptomics Analysis
Transcriptome data were retrieved from the Prostate Cancer Transcriptome Atlas (http://www.
thepcta.org/, v1.0.1) [21], comprised of 1321 clinical specimens from 38 PCa cohorts. One-way ANOVA
testing was used to detect associations with disease course/progression. Disease progression was
defined across the following subgroups: benign, GS < 7, GS = 7, GS > 7 and mCRPC.
3. Results
3.1. Proteomics Analysis
Tissue proteomics profiling data were acquired from 22 fresh-frozen tissue samples including 17
from patients diagnosed with PCa (n = 5 GS6, n = 5 GS7 (3 + 4), n = 2 GS8 and n = 5 GS9) and 5 from
patients with BPH. There was no significant difference in age between patients groups (p = 0.7243),
with median ages of 66 (Interquartile Range (IR): 64.75–71.50) and 66 (IR: 63.50–76.50) for patients
with PCa and BPH, respectively, whereas the median prostate-specific antigen (PSA) levels differed
significantly (PSA level of 19.9 ng/mL (IR: 13.38–39.35) and 0.9 ng/mL (IR: 0.78–1.58) for patients with
cancer diagnosis and benign pathology, respectively, p = 0.0009). Clinical and demographic data from
the study cohort are presented in Table S1.
Following strict criteria for data processing, proteome analysis resulted in the identification of
1433 proteins (on average, 846 protein identifications per sample). A comparable number of proteins
was identified in both groups (p = 0.4106, Kruskal–Wallis test), with an average of 885 and 834 identified
proteins in patients with BPH and PCa, respectively (Figure 1A). In addition, there was a significant
correlation (p < 0.05) in protein abundance across individual samples (Figure 1B), with a median
Spearman Rho correlation coefficient of 0.68 (IR: 0.65–0.74). A total of 1060 (out of 1433) proteins
was identified in >30% of samples (Figure 1C). Serum albumin (ALB), actin, gamma-enteric smooth
muscle (ACTG2), filamin-A (FLNA), myosin-11 (MYH11), desmin (DES), transgelin (TAGLN), collagen
alpha-3(VI) chain (COL6A3), haemoglobin subunit beta (HBB), actin, cytoplasmic 1 (ACTB) and histone
H2A type 1-H (HIST1H2AH) were among top 10 highly abundant proteins in the dataset (Figure 1D).
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Figure 1. Tissue proteome characterization: (A) Boxplots representing the number of proteins 
identified in prostate tissue samples from patients with benign prostatic hyperplasia (BPH) and 
prostate cancer (PCa). (B) Graphical representation of the correlation matrix for normalized protein 
abundances across the individual samples: the Spearman Rho correlation coefficient is colour coded. 
All relationships were significant at p < 0.05. (C) The data completeness plot reflects representation of 
the number of proteins identified in the specific number of samples. The number of proteins identified 
in more than 30%, 60% and 90% of samples are indicated. (D) Graphical representation of protein 
rank against the average protein abundance (log10) calculated based on all analysed samples (n = 22): 
Ten proteins with the highest abundance are highlighted in red. Abbreviations: ALB—serum 
albumin, ACTB—actin, cytoplasmic 1, ACTG2—actin, gamma-enteric smooth muscle, BPH—benign 
prostatic hyperplasia, COL6A3—collagen alpha-3(VI) chain, DES—desmin, FLNA—filamin-A, 
HBB—haemoglobin subunit beta, HIST1H2AH—histone H2A type 1-H, MYH11—myosin-11, PCa—
prostate cancer and TAGLN—transgelin. 
3.2. Differences in Protein Abundance Between Patients with PCa and BPH 
A total of 276 proteins was found to be significantly altered (p < 0.05, Mann Whitney test) 
between samples from patients with PCa and BPH (Figure 2A). To increase confidence in the detected 
differences, only proteins detected in >30% of the samples were considered. Following these criteria 
and upon removing proteins originating from blood/plasma, 145 proteins (defined for the purpose 
of this manuscript as “PCa signature”) were considered for subsequent evaluation (Figure 2A). The 
latter included 72 and 73 proteins being up- and downregulated in cancer in comparison to benign 
tissue, respectively. The list of differentially abundant proteins is presented in Table S2. 
To link differentially abundant proteins to disease pathophysiology, bioinformatics analysis was 
conducted. The top 3 protein classes represented in the PCa signature included metabolic 
interconversion enzymes, cytoskeletal proteins and nucleic acid binding proteins (Figure 2B). 
Proteins belonging to metabolic interconversion enzymes included (among others) dehydrogenases 
(including retinal dehydrogenase 2 (ALDH1A2), NADH-ubiquinone oxidoreductase 75 kDa subunit 
(NDUFS1), aldehyde dehydrogenase X (ALDH1B1), succinate (SDHA), 6-phosphogluconate (PGD), 
Figure 1. Tissue proteome characterization: (A) Boxplots representing the number of proteins
identified in prostate tissue samples from patients with benign prostatic hyperplasia (BPH) and
prostate cancer (PCa). (B) Graphical representation of the correlation matrix for normalized protein
abundances across the individual samples: the Spearman Rho correlation coefficient is colour
coded. All relationships were significant at p < 0.05. (C) The data completeness plot reflects
representation of the number of proteins identified in the specific number of samples. The number
of proteins identified in more than 30%, 60% and 90% of samples are indicated. (D) Graphical
representation of protein rank against the average protein abundance (log10) calculated based
on all analysed samples (n = 22): Ten proteins with the highest abundance are highlighted
in red. Abbreviations: ALB—serum albumin, ACTB—actin, cytoplasmic 1, ACTG2—actin,
gamma-enteric smooth muscle, BPH—benign prostatic hyperplasia, COL6A3—collagen alpha-3(VI)
chain, DES—desmin, FLNA—filamin-A, HBB—haemoglobin subunit beta, HIST1H2AH—histone H2A
type 1-H, MYH11—myosin-11, PCa—prostate cancer and TAGLN—transgelin.
3.2. Differences in Protein Abundance between Patients with PCa and BPH
A total of 276 proteins was found to be significantly altered (p < 0.05, Mann Whitney test)
between samples from patients with PCa and BPH (Figure 2A). To increase confidence in the detected
differences, only proteins detected in >30% of the samples were considered. Following these criteria
and upon removing proteins originating from blood/plasma, 145 proteins (defined for the purpose of
this manuscript as “PCa signature”) were considered for subsequent evaluation (Figure 2A). The latter
included 72 and 73 proteins being up- and downregulated in cancer in comparison to benign tissue,
respectively. The list of differentially abundant proteins is presented in Table S2.
To link differentially abundant proteins to disease pathophysiology, bioinformatics analysis
was conducted. The top 3 protein classes represented in the PCa signature included metabolic
interconversion enzymes, cytoskeletal proteins and nucleic acid binding proteins (Figure 2B).
Proteins belonging to etabolic interconversion enzymes included (among others) dehydrogenases
(including retinal dehydrogenase 2 (ALDH1A2), NADH-ubiquinone oxidoreductase 75 kDa subunit
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(NDUFS1), aldehyde dehydrogenase X (ALDH1B1), succinate (SDHA), 6-phosphogluconate (PGD),
sorbitol (SORD) and methylmalonate-semialdehyde (ALDH6A1) dehydrogenases, and glyoxylate
reductase/hydroxypyruvate reductase (GRHPR)); peroxidases (e.g., catalase (CAT), peroxiredoxin-6
(PRDX6) and phospholipid hydroperoxide glutathione peroxidase (GPX4)); oxidases (e.g., cytochrome
c oxidase subunit 5B (COX5B)), hydratases (aconitate hydratase (ACO2) and bifunctional purine
biosynthesis protein ATIC (ATIC)) and others. Examples of cytoskeletal proteins included PDZ and
LIM domain protein 5 (PDLIM5), coronin-1B (CORO1B), cysteine and glycine-rich protein 2 (CSRP2),
whereas among nucleic acid binding proteins were poly(rC)-binding protein 1 (PCBP1), small nuclear
ribonucleoprotein Sm D3 (SNRPD3) and interleukin enhancer-binding factor 3 (ILF3).
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Figure 2. Protein differences between patients with PCa and BPH: (A) Volcano plot. Proteins that were
identified only in one of the two groups were not plotted. The latter covers 217 and 50 proteins found
solely in the case (PCa) and the control (BPH) groups, respectively. Differentially abundant proteins
(significant change in the abundance (p < 0.05), detected in more than 30% of samples) are shown
in red. (B) Distribution of protein classes of differentially expressed proteins: Protein classes were
defined according to the Panther Classification System. Information on the protein class was available
for 88 out of 145 differentially abundant proteins. (C) Graphical representation of the enrichment
analysis based on Molecular Signatures Database (MSigDB) hallmark gene set ontology: the ten most
significantly enriched terms are presented. p-values were calculated using the Banjamini–Hochberg
procedure. Abbreviations: BPH—benign prostatic hyperplasia, MSigDB—Molecular Signatures
Database, MYC—Myc proto-oncogene and PCa—prostate cancer.
Consistent with the above observations, the Kegg pathway enrichment analysis (Table 1)
demonstrated that most of the significantly enriched pathways were related to metabolism (e.g.,
metabolic pathways, tricarboxylic acid (TCA) cycle, carbon metabolism, glutathione metabolism,
glyoxylate and dicarboxylate metabolism, pentose and glucuronate interconversions). Other enriched
pathways included protein processing in endoplasmic reticulum (ER), interleukin 17 (IL-17) signalling
pathways and lysosomes. The enrichment in MSigDB hallmark gene sets (Table 2, Figure 2C)
revealed associations with oxidative phosphorylation, xenobiotic metabolism, fatty acid metabolism,
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adipogenesis, heme metabolism or protein secretion, in line with the enrichment analysis based on
Kegg. Other hallmarks (not covered by Kegg analysis) included Myc proto-oncogene (MYC) targets,
androgen response, oestrogen response late and PI3K/AKT/mTOR signalling.
Table 1. Pathway enrichment analysis: List of significantly enriched pathways (false discovery rate
(FDR) < 0.05).
Kegg Pathway FDR Coverage (%) Associated Proteins
TCA cycle 8.10 × 10−3 13.33 ACLY, ACO2, IDH2, SDHA
Metabolic pathways 8.10 × 10−3 1.84
ACACA, ACLY, ACO2, AKR1B1,
ALDH1A2, ALDH1B1, ALDH6A1, ASAH1,
ATIC,CES1, COX5B, DCXR, EPRS1,
GRHPR, HEXB, IDH2, NANS, NDUFS1,
PGD, PRDX6, RPN1, SDHA, SORD
Lysosome 8.10 × 10−3 5.69 ASAH1, HEXB, LAMP1, LAMP2, NPC2,PSAP, SCARB2
Carbon metabolism 1.17 × 10−2 5.17 ACO2, ALDH6A1, CAT, IDH2, PGD,SDHA
Glutathione metabolism 2.20 × 10−2 8.00 GPX4, GSTP1, IDH2, PGD
IL-17 signalling pathway 2.20 × 10−2 5.43 HSP90AB1, LCN2, MAPK6, S100A8,S100A9
Glyoxylate and
dicarboxylate metabolism 3.47 × 10−2 10.71 ACO2, CAT, GRHPR
Protein processing in ER 3.47 × 10−2 3.73 CRYAB, HSP90AB1, P4HB, RPN1,SEC61A1, UGGT1
Pentose and glucuronate
interconversions 4.65 × 10−2 8.82 AKR1B1, DCXR, SORD
Proteins that were upregulated in patients with PCa in comparison to controls are labelled in green, while proteins
labelled in red were downregulated in PCa. The abbreviations are listed in the abbreviation section.
Table 2. Shortlisted biological hallmarks that were found to be significantly enriched against Molecular
Signatures Database (MSigDB) hallmark gene sets.
Hallmark p-Value Coverage (%) Associated Proteins
MYC targets v1 1.64 × 10−5 5.00
EEF1B2, EPRS1, HSP90AB1, PA2G4, PCBP1,
PSMB2, RPS5, SNRPD3, RACK1,
HNRNPA3
Oxidative phosphorylation 5.15 × 10−5 4.50 ACO2, SLC25A6, COX5B, ECI1, GPX4,IDH2, ALDH6A1, NDUFS1, SDHA
Xenobiotic metabolism 5.15 × 10−5 4.50 ACO2, CA2, CAT, CES1, FBLN1, PGD,PDLIM5, DCXR, DHRS7
Fatty acid metabolism 5.51 × 10−4 4.43 ACO2, CA2, ECI1, HPGD, SDHA, GRHPR,PRDX6
Adipogenesis 1.92 × 10−3 3.50 ACLY, ACO2, CAT, COL4A1, GPX4,LAMA4, DHRS7, PRDX6
Protein secretion 2.22 × 10−3 5.21 AP2B1, ARCN1, ARF1, KRT18, LAMP2
Androgen response 2.41 × 10−3 4.95 HPGD, KRT8, PA2G4, SORD, PDLIM5
Oestrogen response late 6.88 × 10−3 3.00 CA2, FLNB, IDH2, S100A9, SORD, DCXR
Heme metabolism 6.88 × 10−3 3.00 CA1, CA2, CAT, LAMP2, ALDH6A1,SELENBP1
PI3K/AKT/mTOR signalling 1.60 × 10−2 3.81 ACACA, ARF1, UBE2N, YWHAB
Top 10 hallmarks selected based on the significance level (Benjamini–Hochberg adjusted p-value) are shown. Proteins
that were upregulated in patients with PCa in comparison to controls are labelled in green, while proteins labelled
in red were downregulated in PCa. The abbreviations are listed in the abbreviation section.
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3.3. Association of Protein Abundance with PCa Progression
Significantly enriched Kegg pathways (Table 1) and MSigDB hallmarks (Table 2) were represented
by a total of 67 proteins, with most proteins that act in metabolic pathways identified with higher
expression in malignant compared to nonmalignant prostate tissue. For those 67 proteins, association
with cancer progression (as represented by increased GS) was investigated by Spearman correlation.
Significant correlation of protein abundance with progression was observed for 25 proteins (i.e.,
23 positively correlated and 2 negatively correlated; Table 3). In most cases, the direction of the
association was in line with the direction of the fold change when comparing protein abundance
between patients with PCa and BPH, with the exception of aldo-keto reductase family 1 member B1
(AKR1B1), carbonic anhydrase 2 (CA2) and acetyl-CoA carboxylase 1 (ACACA). These three proteins
showed significantly lower abundance in cancer in comparison to controls (p < 0.05), while their
abundance was positively correlated with GS (p < 0.05). For the shortlisted 25 proteins, association
with disease progression was further evaluated in an independent transcriptomics dataset available
from the Prostate Cancer Transcriptome Atlas [21]. The significant association with disease progression
at the mRNA level was found for 21 out of the 25 proteins (p < 0.05, ANOVA, Table 3), supporting
validity of the proteomics findings.
To find connections between these 21 proteins and to identify pathways/hallmarks that are
consistently affected during disease development, protein–protein interaction analysis was conducted.
As a result of this analysis, an interactome network comprised of 15 interconnected proteins with a total
number of 22 edges and a significant protein–protein interaction enrichment p-value (p = 0.000167) was
constructed (Figure 3). The latter indicates that proteins included in the network reveal a significantly
higher number of interactions between each other than expected when analysing a random protein list
of comparable size. This significant enrichment implies that the proteins belonging to the network
are likely biologically connected. To further investigate their link to biology, pathways/hallmarks in
which these proteins act were overlaid on the interactome network (Figure 3). Interconnection was
observed between three pathways/hallmarks, i.e., MYC targets, oxidative phosphorylation and protein
processing in ER. Among the interacting proteins involved in these pathways/hallmarks, receptor of
activated protein C kinase 1 (RACK1) and bifunctional glutamate/proline–tRNA ligase (EPRS1), both
being MYC targets, appear to be connecting nodes with proteins belonging to protein processing in ER
and oxidative phosphorylation, while ADP/ATP translocase 3 (SLC25A6), protein transport protein
Sec61 alpha isoform 1 (SEC61A1), dolichyl-diphosphooligosaccharide-protein glycosyltransferase
subunit 1 (RPN1) and proliferation-associated protein 2G4 (PA2G4) are connecting nodes with only
one other pathway/hallmark. Heat shock protein HSP 90-beta (HSP90AB1, HSP 90) is a member of
protein processing in ER as well as a MYC target. Distribution of the protein abundance for these
proteins, representing connecting nodes, is shown in Figure 4.
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network of proteins associated with progression at protein and mRNA levels. Nodes
(proteins) connecting all three pathways/hallmarks are highlighted in red, while those nodes
connecting between two pathways/hallmarks are marked in purple. Disconnected nodes in
the network are not shown. Colour clouds represent proteins belonging to the indicated
pathway/hallmark. Abbreviations: ACACA—acetyl-CoA carboxylase 1, ALDH1B1—aldehyde
dehydrogenase X, mitochondrial, ALDH6A1—methylmalonate-semialdehyde dehydrogenase
(acylating), AKR1B1—aldo-keto reductase family 1 member B1, ARF1—ADP-ribosylation
factor 1, EPRS1—bifunctional glutamate/proline–tRNA ligase, ER—endoplasmic reticulum,
GRHPR—glyoxylate reductase/hydroxypyruvate reductase, HSP90AB1—heat shock protein HSP
90-beta, LAMP1—lysosome-associated membrane glycoprotein 1, MYC— Myc proto-oncogene,
P4HB—protein disulphide-isomerase, PA2G4—proliferation-associated protein 2G4, RACK1—receptor
of activated protein C kinase 1, RPN1—dolichyl-diphosphooligosaccharide–protein glycosyltransferase
subunit 1, SEC61A1—protein transport protein Sec61 subunit alpha isoform 1 and SLC25A6—ADP/ATP
translocase 3.
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Figure 4. Boxplots representing distribution of the normalized protein abundance according to
the disease progression. Abbreviations: BPH—benign prostatic hyperplasia, EPRS1—bifunctional
glutamate/proline–tRNA ligase, GS—Gleason score, HSP90AB1—heat shock protein HSP 90-beta,
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Table 3. List of differentially abundant proteins mapped to enriched pathways/hallmarks and associated with Gleason score (GS).
Protein Name Symbol
Proteomics Transcriptomics
Pathway/HallmarkAvg. Abundance
PCa (±SD)
Avg.
Abundance
BPH (±SD)
Fold Change
(PCa/BPH)
p-Value
(MW) Rho
p-Value
(Spearman)
p-Value
(ANOVA)
Cytochrome c oxidase
subunit 5B,
mitochondrial
COX5B 35.57 (±46.07) 0.00 (±0.00) Only in PCa 2.38 × 10−2 0.71 1.51 × 10−3 0.373
Metabolic pathways,
Oxidative
phosphorylation
Elongation factor 1-beta EEF1B2 49.80 (±54.02) 0.00 (±0.00) Only in PCa 5.62 × 10−3 0.52 3.12 × 10−2 0.173 MYC targets v1
Bifunctional
glutamate/proline–tRNA
ligase
EPRS1 113.27 (±111.41) 2.55 (±5.71) 44.39 1.08 × 10−2 0.56 1.88 × 10−2 <0.001 Metabolic pathways,MYC targets v1
Enoyl-CoA delta
isomerase 1,
mitochondrial
ECI1 83.71 (±144.87) 2.43 (±5.43) 34.46 4.25 × 10−2 0.55 2.08 × 10−2 <0.001
Oxidative
phosphorylation, Fatty
acid metabolism
PDZ and LIM domain
protein 5 PDLIM5 49.56 (±95.10) 1.76 (±3.94) 28.15 1.60 × 10−2 0.51 3.79 × 10−2 <0.001
Xenobiotic metabolism,
Androgen response
Methylmalonate-
semialdehyde
dehydrogenase
(acylating),
mitochondrial
ALDH6A1 320.75 (±466.95) 13.95 (±31.19) 22.99 9.02 × 10−3 0.56 2.01 × 10−2 <0.001
Metabolic pathways,
Carbon metabolism,
Oxidative
phosphorylation, Heme
metabolism
Protein transport protein
Sec61 subunit alpha
isoform 1
SEC61A1 30.88 (±32.34) 1.86 (±4.16) 16.59 2.46 × 10−2 0.75 5.71 × 10−4 <0.001 Protein processing in ER
Coatomer subunit delta ARCN1 101.90 (±101.48) 10.27 (±10.20) 9.92 1.50 × 10−2 0.57 1.62 × 10−2 0.302 Protein secretion
Proliferation-associated
protein 2G4 PA2G4 100.95 (±102.47) 17.45 (±24.51) 5.79 4.89 × 10−2 0.64 5.43 × 10−3 <0.001
MYC targets v1,
Androgen response
Lysosome-associated
membrane glycoprotein 1 LAMP1 240.92 (±193.22) 42.06 (±53.65) 5.73 2.29 × 10−2 0.58 1.43 × 10−2 0.036 Lysosome
Receptor of activated
protein C kinase 1 RACK1 337.82 (±237.92) 65.47(±34.60) 5.16 6.10 × 10−3 0.67 3.38 × 10−3 <0.001 MYC targets v1
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Table 3. Cont.
Protein Name Symbol
Proteomics Transcriptomics
Pathway/HallmarkAvg. Abundance
PCa (±SD)
Avg.
Abundance
BPH (±SD)
Fold Change
(PCa/BPH)
p-Value
(MW) Rho
p-Value
(Spearman)
p-Value
(ANOVA)
Glyoxylate
reductase/hydroxypyruvate
reductase
GRHPR 96.02 (±81.68) 22.89 (±16.11) 4.19 9.73 × 10−3 0.55 2.20 × 10−2 0.010
Metabolic pathways,
Glyoxylate and
dicarboxylate
metabolism, Fatty acid
metabolism
Protein
disulphide-isomerase P4HB 849.09 (±736.21) 205.58 (±45.05) 4.13 2.83 × 10−2 0.62 8.49 × 10−3 <0.001 Protein processing in ER
ADP-ribosylation factor 1 ARF1 274.51 (±227.49) 81.88 (±49.35) 3.35 3.44 × 10−2 0.57 1.78 × 10−2 <0.001
Protein secretion,
PI3K/AKT/mTOR
signalling
Dolichyl-
diphosphooligosaccharide–
protein
glycosyltransferase
subunit 1
RPN1 154.05 (±107.39) 50.38 (±29.21) 3.06 3.44 × 10−2 0.50 4.17 × 10−2 0.005 Metabolic pathways,Protein processing in ER
ADP/ATP translocase 3 SLC25A6 944.05 (±505.41) 359.42 (±146.11) 2.63 1.88 × 10−2 0.75 4.71 × 10−4 <0.001 Oxidativephosphorylation
Heat shock protein HSP
90-beta HSP90AB1 1251.54 (±791.26) 482.75 (±165.56) 2.59 1.52 × 10−2 0.75 5.42 × 10−4 0.001
IL-17 signalling pathway,
Protein processing in ER,
MYC targets v1
Isocitrate dehydrogenase
(NADP), mitochondrial IDH2 546.27 (±279.70) 243.42 (±104.52) 2.24 2.83 × 10−2 0.57 1.72 × 10−2 0.017
TCA cycle, Metabolic
pathways, Carbon
metabolism, Glutathione
metabolism, Oxidative
phosphorylation,
Oestrogen response late
14-3-3 protein beta/alpha YWHAB 684.20 (±305.98) 324.49 (±159.83) 2.11 9.73 × 10−3 0.85 1.93 × 10−5 0.218 PI3K/AKT/mTORsignalling
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Table 3. Cont.
Protein Name Symbol
Proteomics Transcriptomics
Pathway/HallmarkAvg. Abundance
PCa (±SD)
Avg.
Abundance
BPH (±SD)
Fold Change
(PCa/BPH)
p-Value
(MW) Rho
p-Value
(Spearman)
p-Value
(ANOVA)
Ubiquitin-conjugating
enzyme E2 N UBE2N 314.95 (±140.93) 159.39 (±58.37) 1.98 1.88 × 10−2 0.63 7.16 × 10−3 <0.001
PI3K/AKT/mTOR
signalling
15-hydroxyprostaglandin
dehydrogenase (NAD(+)) HPGD 37.40 (±37.39) 84.41 (±33.97) 0.44 3.16 × 10−2 −0.74 6.69 × 10−4 0.016
Fatty acid metabolism,
Androgen response
Acetyl-CoA carboxylase 1 ACACA 9.93 (±20.78) 29.28 (±23.17) 0.34 4.09 × 10−2 0.60 1.16 × 10−2 <0.001
Metabolic pathways,
PI3K/AKT/mTOR
signalling
Aldehyde dehydrogenase
X, mitochondrial ALDH1B1 11.64 (±11.27) 40.54 (±37.31) 0.29 1.81 × 10−2 −0.49 4.38 × 10−2 <0.001 Metabolic pathways
Aldo-keto reductase
family 1 member B1 AKR1B1 100.00 (±138.86) 377.89 (±231.11) 0.26 6.09 × 10−3 0.65 4.61 × 10−3 <0.001
Metabolic pathways,
Pentose and glucuronate
interconversions
Carbonic anhydrase 2 CA2 23.15 (±39.16) 191.60 (±176.21) 0.12 3.39 × 10−3 0.78 2.32 × 10−4 <0.001
Xenobiotic metabolism,
Fatty acid metabolism,
Oestrogen response late,
Heme metabolism
Fold change (increase in green; decrease in red) calculated based on the average protein abundance in patients with PCa in comparison to average protein abundance in patients with BPH
as well as unadjusted p-values (Mann Whitney test, MW) are provided. The results of the correlation analysis of protein abundance with GS are also given, including Spearman Rho
correlation coefficient and relevant p-values. Association of mRNA abundance with disease progression retrieved from the Prostate Cancer Transcriptome Atlas is also presented. The
abbreviations are listed in the abbreviations section.
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4. Discussion
This proof-of-concept study aimed to characterize protein changes in tissue that occur during
PCa development and to identify affected molecular pathways. A high number of proteins could be
identified as significantly affected, many of these in agreement with reports on the transcriptome level.
In silico analysis of proteins differentially abundant between PCa and BPH clearly indicated that the
vast majority of pathways were related to metabolism. Metabolic reprograming is one of the main
cancer hallmarks [22], and its role in the PCa initiation, progression and resistance to therapies has been
extensively studied [23–25]. Further investigation of the individual metabolic pathways revealed that
many of them are well-established hallmarks of PCa, including, among others, fatty acid metabolism,
TCA cycle and oxidative phosphorylation. Fatty acid metabolism has been recognized as a dominant
process responsible for energy production in PCa cells due to slow glycolysis [26]. Fatty acid synthesis
is required for energy production, membrane synthesis and posttranslational modifications [27]. Along
these lines, previous studies have demonstrated also acceleration of the TCA cycle in the context of
PCa [25], representing one of the key features of prostate malignant transformation. In contrast, normal
prostate epithelial cells are specialized to produce and secrete citrate, a component of prostatic fluid, due
to inhibition of the TCA cycle. In concordance with the activation of TCA cycle, our analysis revealed
also an activation of oxidative phosphorylation. In comparison to other malignancies, PCa depends
more on oxidative phosphorylation instead of glycolysis [25,28]. In addition to the metabolic changes,
other pathways and biological functions that have been previously linked to PCa were also predicted
based on proteomics analysis. Among others, IL-17 signalling [29], protein processing in ER [30,31],
androgen signalling [32], PI3K/AKT/mTOR signalling [33] or MYC targets [34] were significantly
enriched based on the proteomic PCa signature. The role of the most promising pathways is further
discussed below. The identification of pathways/hallmarks that have been previously reported in the
context of PCa serves as a positive control for our study and supports its validity.
To date, numerous molecular subtypes have been defined for PCa [6–8]. Thus, classification of
samples based on clinical characteristics might not be optimal, also reflected by the moderate success
of treatment. Taking this into consideration, we investigated PCa progression (expressed as increase in
GS) based on the hypothesis that cancer progresses as a continuum and that proteins that are truly
associated with this process are gradually and consistently changed. To further enhance the validity
of the findings, the association with disease progression was also assessed at the mRNA level. This
complementary assessment through cross-correlation of different –omics traits is expected to better
reflect the clinical reality and to increase the validity of individual observations. The approach of
cross-correlating proteomics and transcriptomics data has previously shown increased validity [35].
Such cross-omics analysis followed by interactome analysis highlighted prominent alterations in MYC
targets, oxidative phosphorylation and protein processing in the ER. Interestingly, these processes seem
to be interconnected, with MYC targets linking the latter two pathways. These pathways/hallmarks
appear activated during PCa development, and abundance of the associated proteins (also verified at
the mRNA level) was found to increase along with disease progression. Multiple evidence to support
the implication of these pathways/hallmarks in the context of PCa, along with their interconnections,
was collected, as discussed below.
MYC is a proto-oncogene frequently overexpressed in PCa [36] and associated with PCa
progression [37]. In principle, MYC increases the expression of genes involved in cell growth
and proliferation, survival of cancer cells [37,38] and regulation of cellular metabolism [39]. It promotes
transcription of androgen receptor (AR) and enhances the stability of full-length AR and its splice
variants [40]. Our study revealed several MYC targets being consistently upregulated during PCa
development, including RACK1, HSP 90, EPRS1, and PA2G4. RACK1 [41], HSP 90 [42] and PA2G4 [43]
have been reported previously in the context of PCa. RACK1 is a scaffolding protein involved in
recruitment, assembly as well as regulation of signalling molecules and has been observed to promote
proliferation, invasion and metastasis of PCa both in vitro and in vivo [41]. The molecular chaperone
HSP 90 is involved in protein folding and maintaining protein stability (including AR) and has been
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reported to be overexpressed in many cancers, including PCa [42]. Considering its interactions with
AR, HSP 90 was proposed as a potential therapeutic target in PCa [42]. PA2G4 is involved in cellular
proliferation and regulation of gene expression and is also a corepressor of the AR. Significant increase
in the protein expression from normal to hormone refractory PCa was reported previously, also
correlating with the nuclear expression of AR in normal adjacent and cancer tissue [43].
Our analysis showed a connection between MYC targets and protein processing in ER. In fact,
activation of ER stress/the unfolded protein response has been linked to cancer, including also PCa [31].
The unfolded protein response represents protective mechanisms of cancer cells under unfavourable
conditions (e.g., hypoxia, oxidative stress and eventually ER stress). During the unfolded protein
response, inositol requiring-enzyme 1 alpha (IRE1α)/X-box-binding protein 1 (XBP1) signalling is
activated [31]. It has been shown that androgens regulate expression of genes associated with ER
stress, including the IRE1α-XBP1 arm [31]. Among the proteins contributing to the interactome
network described in our study and associated with protein processing in ER, we found SEC61A1
(SEC61 translocon subunit), a component of the protein translocation machinery (together with
SEC62 and SEC63) mediating transport across ER [44]. SEC61A1 is a downstream XBP1 target gene,
downregulated upon inhibition of XBP1 splicing with MKC-3946 treatment in multiple myeloma
cells [45]. Nevertheless, the role of SEC61A1 has not been investigated in the context of PCa. Another
component of the ER translocation machinery (although not found in our proteomics analysis), SEC62,
has been investigated in PCa. SEC62 knockdown reduced the migration and invasion of PCa cells [46],
and the overproduction of SEC62 protein in PCa tissue was correlated with GS [46]. In addition, our
analysis identified RPN1, one of the subunits of the oligosaccharyl transferase complex, also being
associated with the SEC61 complex. RPN1 is involved in N-glycosylation and was found (among
other genes) to be downregulated upon treatment of androgen-independent PCa xenografts with 17β
oestradiol that led to inhibition of tumour growth [47]. Protein disulphide-isomerase (P4HB) was
another protein identified in our network as a member of protein processing in the ER pathway. P4HB
is responsible for the formation, opening and reorganization of disulphide bonds. When present
in high concentration, it acts as a chaperone that protects from the generation of misfolded protein
aggregates. The P4HB gene was found to be significantly increased in PCa in comparison to the normal
prostate gland [48], in agreement with our data.
Based on the available literature and in line with our results, protein processing in ER appears to
be interconnected with MYC signalling [49]. Treatment with an IRE1α inhibitor inhibited PCa growth
in vitro and in vivo, indicating that the IRE1α/XBP1 pathway promotes PCa through activation of
c-MYC signalling [50]. Based on these findings, inhibition of IRE1α/XBP1 was proposed as a possible
strategy for PCa treatment. In another study, interaction between IRE1α and RACK1 was crucial
for the activation of IRE1α/XBP1 signalling upon unfolded protein response induced by sorafenib in
hepatocellular carcinoma cells [51], further supporting the interconnection between MYC signalling
and ER processes.
The data presented here also highlighted oxidative phosphorylation as a hallmark in PCa and
indicated its possible connection with MYC targets. Changes in mitochondrial metabolism covering
oxidative phosphorylation are one of the cancer hallmarks [52]. A recent study demonstrated alterations
in oxidative phosphorylation in paired benign and malignant human prostate tissue samples [28],
supporting the validity of our findings. Among the proteins mapped to oxidative phosphorylation
in our network, ALDH6A1, an enzyme catalysing the oxidative decarboxylation of malonate and
methylmalonate semialdehydes to acetyl- and propionyl-CoA, was found to be overexpressed in PCa
tissues in comparison to normal prostatic tissue and was also significantly associated with lymphatic
invasion in PCa [53]. In addition, SLC25A6, involved in exchanging ADP from cytoplasm with ATP
from mitochondria through the mitochondrial membrane, was also found in our analysis among the
proteins involved in oxidative phosphorylation. Furthermore, evidence supporting the connection
of MYC with oxidative phosphorylation exists. Among others, MYC is known to be involved in
the stimulation of mitochondrial biogenesis [54]. Previous transcriptomics analysis revealed several
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nuclear genes encoding mitochondrial proteins being downstream targets of MYC, including among
others proteins involved in oxidative phosphorylation [54], which supports our findings.
Our study presents with some limitations. Since this was a proof-of-concept study, the sample
size was not adequate to perform multiple testing correction. Therefore, identification of differentially
expressed proteins was based on the unadjusted p-values. Even though, our findings were in line with
the existing literature and, for several proteins, a consistent association with disease progression was
observed at both the protein and mRNA levels. Further validation of the findings in the context of a
statistically well-powered study is required.
5. Conclusions
Tissue proteome analysis allowed characterization of molecular changes associated with PCa
development. Among the most promising pathways and biological functions consistently affected in
disease onset and progression were protein processing in ER, oxidative phosphorylation and MYC
targets. These pathways also appear to be linked with each other, which is supported by existing
literature. However, their interconnections through the proteins identified in our study are mostly
novel and require further validation. These molecular linkers may also serve as potential candidates
for drug targeting.
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Abbreviations
ACACA acetyl-CoA carboxylase 1
ACLY ATP-citrate synthase
ACO2 aconitate hydratase, mitochondrial
ACTB actin, cytoplasmic 1
ACTG2 actin, gamma-enteric smooth muscle
AKR1B1 aldo-keto reductase family 1 member B1
ALB serum albumin
ALDH1A2 retinal dehydrogenase 2
ALDH1B1 aldehyde dehydrogenase X, mitochondrial
ALDH6A1 methylmalonate-semialdehyde dehydrogenase (acylating), mitochondrial
AP2B1 AP-2 complex subunit beta
AR androgen receptor
ARCN1 coatomer subunit delta
ARF1 ADP-ribosylation factor 1
ASAH1 acid ceramidase
ATIC bifunctional purine biosynthesis protein ATIC
BPH benign prostatic hyperplasia
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CA1 carbonic anhydrase 1
CA2 carbonic anhydrase 2
CAT catalase
CES1 liver carboxylesterase 1
COL4A1 collagen alpha-1(IV) chain
COL6A3 collagen alpha-3(VI) chain
CORO1B coronin-1B
COX5B cytochrome c oxidase subunit 5B, mitochondrial
CRPC castration-resistant prostate cancer
CRYAB alpha-crystallin B chain
CSRP2 cysteine and glycine-rich protein 2
DCXR L-xylulose reductase
DES desmin
DHRS7 dehydrogenase/reductase SDR family member 7
ECI1 enoyl-CoA delta isomerase 1, mitochondrial
EEF1B2 elongation factor 1-beta
EPRS1 bifunctional glutamate/proline–tRNA ligase
ER endoplasmic reticulum
FBLN1 fibulin-1
FDR false discover rate
FLNA filamin-A
FLNB filamin-B
GPX4 phospholipid hydroperoxide glutathione peroxidase
GRHPR glyoxylate reductase/hydroxypyruvate reductase
GS Gleason score
GSTP1 glutathione S-transferase P
HBB haemoglobin subunit beta
HCD higher-energy collisional dissociation
HEXB beta-hexosaminidase subunit beta
HIST1H2AH histone H2A type 1-H
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3
HPGD 15-hydroxyprostaglandin dehydrogenase (NAD(+))
HSP90/HSP90AB1 heat shock protein HSP 90-beta
IDH2 isocitrate dehydrogenase (NADP), mitochondrial
IL-17 interleukin 17
ILF3 interleukin enhancer-binding factor 3
IR interquartile range
IRE1α inositol requiring-enzyme 1 alpha
Kegg Kyoto encyclopedia of genes and genomes
KRT18 keratin, type I cytoskeletal 18
KRT8 keratin, type II cytoskeletal 8
LAMA4 laminin subunit alpha-4
LAMP1 lysosome-associated membrane glycoprotein 1
LAMP2 lysosome-associated membrane glycoprotein 2
LC-MS/MS liquid chromatography coupled to tandem mass spectrometry
LCN2 neutrophil gelatinase-associated lipocalin
MAPK6 mitogen-activated protein kinase 6
mCRPC metastatic castration-resistant prostate cancer
MSigDB Molecular Signatures Database
MW Mann Whitney test
MYC Myc proto-oncogene
MYH11 myosin-11
NANS sialic acid synthase
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NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial
NPC2 NPC intracellular cholesterol transporter 2
P4HB protein disulphide-isomerase
PA2G4 proliferation-associated protein 2G4
PCa prostate cancer
PCBP1 poly(rC)-binding protein 1
PDLIM5 PDZ and LIM domain protein 5
PGD 6-phosphogluconate dehydrogenase, decarboxylating
PRDX6 peroxiredoxin-6
PSA prostate specific antigen
PSAP prosaposin
PSMB2 proteasome subunit beta type-2
RACK1 receptor of activated protein C kinase 1
RPN1 dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1
RPS5 ribosomal protein S5
S100A8 protein S100-A8
S100A9 protein S100-A9
SCARB2 lysosome membrane protein 2
SDHA succinate dehydrogenase (ubiquinone) flavoprotein subunit, mitochondrial
SDS-PAGE sodium dodecyl sulphate–polyacrylamide gel electrophoresis
SEC61A1 protein transport protein Sec61 alpha isoform 1
SELENBP1 methanethiol oxidase
SLC25A6 ADP/ATP translocase 3
SNRPD3 small nuclear ribonucleoprotein Sm D3
SORD sorbitol dehydrogenase
TAGLN transgelin
TCA cycle tricarboxylic acid cycle
UBE2N ubiquitin-conjugating enzyme E2 N
UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1
XBP1 X-box-binding protein 1
YWHAB 14-3-3 protein beta/alpha
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